<DOC>
	<DOCNO>NCT00040157</DOCNO>
	<brief_summary>To determine safety efficacy ACH-126,443 treatment adult HIV infection modestly detectable viral load stable triple combination antiretroviral therapy include 3TC .</brief_summary>
	<brief_title>Safety Antiviral Study ACH-126 , 443 ( Beta-L-Fd4C ) Treatment Adults With HIV Infection Modestly Detectable Viral Load .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Adults ≥18 year age Receiving stable triple combination antiretroviral regimen include 3TC , one NRTI either NNRTI protease inhibitor least 4 month ( 16 week ) Demonstration initial viral suppression subsequent rebound define initial virological drop least 0.5 Logs 3TCcontaining regimen Plasma HIV RNA level &gt; 1000 &lt; 30,000 copies/mL two occasion Genotypically document M184V variant HIV RT Clinically stable HIV status AIDSdefining event CD4 &gt; 200 cells/mm3 Basic hematologic chemistry parameter within acceptable limit ( define protocol ) All woman child bear potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L bHCG ) within 72 hour prior start study medication No active opportunistic infection require treatment Subject must able provide write informed consent Baseline laboratory value measure within 28 day initiate study drug follow : HGB≥9.0g/dl HCT≥27 % ( absence blood transfusion erythropoietin treatment precede two week Absolute neutrophil count≥1000 cells/mm ( ^3 ) ( absence ongoing GCSF therapy Platelet count ≥75,000/mm ( ^3 ) AST &lt; 7.0 time upper limit normal ALT ,7.0 time upper limit normal Serum creatinine &lt; 1.1 time upper limit normal Exclusion Criteria Evidence active HBV infection demonstrate HBsAg positivity Hepatitis C coinfection Concurrent systemic antiviral treatment Previous therapy agent significant systemic myelosuppressive cytotoxic potential within 3 month study start expect need therapy study start . Alcohol abuse Pregnancy breastfeed Inability tolerate oral medication AST &gt; 7.0 time upper limit normal ALT &gt; 7.0 time upper limit normal Any clinical condition prior therapy , Investigators opinion , would make subject unsuitable study unable comply dose requirement . Use drug substance antiHBV activity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>treatment experience ,</keyword>
	<keyword>Stable triple anti-retroviral combination therapy HIV-infected ,</keyword>
	<keyword>Achillion</keyword>
</DOC>